BMS-819881 |
رقم الكتالوجGC31479 |
BMS-819881 هو أحد مضادات مستقبل هرمون تركيز الميلانين 1 (MCHR1) ، والذي يربط الفئران MCHR1 بـ Ki من 7 نانومتر
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1197420-05-5
Sample solution is provided at 25 µL, 10mM.
BMS-819881 is a melaninconcentrating hormone receptor 1 (MCHR1) antagonist, which binds rat MCHR1 with a Ki of 7 nM. BMS-819881 also is selective and potent for CYP3A4 activity with an EC50 of 13 μM.
BMS-819881 (Compound 27) is 99.8% binds to rat serum proteins and rat MCHR1 Ki is 7 nM. FLIPR-based assays establish that BMS-819881 is a potent and highly selective MCHR1 functional antagonist. BMS-819881 (Kb=32 nM) effectively blocks MCH stimulated Ca2+ mobilization in heterologous cells overexpressing MCHR1 but fails to inhibit MCH mediated Ca2+ mobilization of cells expressing MCHR2 at 10 μM. No activity is observed upon screening BMS-819881 at 10 μM versus a panel of 20 GPCRs associated with feeding homeostasis. The percent of BMS-819881 binds to serum proteins is species dependent ranging from 99.8%, 99.6%, and 99.3%, respectively, for rat, dog, and monkey. When BMS-819881 is screened for cytochrome P450 (CYP) activity, EC50 values for CYP1A2, CYP2C9, CYP2C19, CYP2D6 are >40 μM; however, the CYP3A4 EC50 is 13 μM[1].
BMS-819881 has moderate terminal elimination half-life (t1/2=5.7 h, 32±8 h, and 14±3 h for rat (1 mg/kg, iv), dog (1 mg/kg, iv), and cynomologous monkey (1 mg/kg, iv))[1].
[1]. Washburn WN, et al. Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate. J Med Chem. 2014 Sep 25;57(18):7509-22.
Kinase experiment: | Membranes from stably transfected HEK-293 cells expressing a mutated (E4Q, A5T) hMCHR1 receptor are prepared and differential centrifugation. Binding experiments are carried out with 0.5-1.0 μg of membrane protein incubated in a total of 0.2 mL in 25 mM HEPES (pH 7.4) with 10 mM MgCl2, 2 mM EGTA, and 0.1% BSA (binding buffer) for 90 min. For competition binding assays, reactions are carried out in the presence of 0.06–0.1 nM [Phe13, [125I]Tyr19]MCH and increasing concentrations of unlabeled test molecules. Reactions are terminated by rapid vacuum filtration over 96-well GFC Unifilter plates precoated with 0.075 mL of binding buffer containing 1% BSA and washed 3 times with 0.4 mL of PBS (pH 7.4) containing 0.01% TX-100. Filters are dried, 0.05 mL of MicroScint 20 is added to each well, and radioactivity is subsequently quantified by scintillation counting on a TopCount microplate scintillation counter. Inhibitory constants are determined by nonlinear least-squares analysis using a four-parameter logistic equation[1]. |
Cell experiment: | Stable HEK-293 cells expressing human MCHR1 or MCHR2 receptor are plated at a density of 50 000 cells/well in 96-well polylysine coated plates and cultured overnight in DMEM (high glucose (4.5 g/mL), 25 mM HEPES, pH 7.4, 10% fetal bovine serum, 1 mM NaCl) at 37°C, 5% CO2 conditions. For assay, the medium is replaced with 90 mL per well dye solution consisting of 3.8 mM Fluo4 AM, 0.04% Pluronic F-127, and 2.5 mM Probencid in base buffer (Hank’s balanced salt solution, 25 mM HEPES, 0.1% BSA). Dye solution is allowed to “load” for 1 h at room temperature in subdued light. Dye is subsequently removed and replaced with 75 mL of base buffer and 75 mL of diluted test compound (e.g., BMS-819881; 10 μM) and incubated for an additional 15 min. Test compound dilution plates are prepared by serial diluting test and reference compounds from 100% DMSO stocks first 1:50 in base buffer and then serially (1:3.26) in base buffer containing 2% DMSO to generate 12 half log test concentrations[1]. |
Animal experiment: | Rats, Dogs, and Cynomologous monkeys [1]PK studies using three species (rat, dog, and cynomologous monkey) are conducted with BMS-819881 administered iv at 1 mg/kg[1]. |
References: [1]. Washburn WN, et al. Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate. J Med Chem. 2014 Sep 25;57(18):7509-22. |
Cas No. | 1197420-05-5 | SDF | |
Canonical SMILES | ClC1=CC=C(C2=CC(N=CN(C3=CC(OC)=C(OC[C@H](O)C4CC4)C=C3)C5=O)=C5S2)C=C1 | ||
Formula | C24H21ClN2O4S | M.Wt | 468.95 |
الذوبان | Soluble in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.1324 mL | 10.6621 mL | 21.3242 mL |
5 mM | 0.4265 mL | 2.1324 mL | 4.2648 mL |
10 mM | 0.2132 mL | 1.0662 mL | 2.1324 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 13 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *